Patent Expiry Watch

Daily infographic: a real drug, whose patent, when it expires, and what happens to the market when it does: the kind of tracking a Portfolio Retainer does continuously, made public one drug at a time.

Oct 27, 2026

Retevmo (Selpercatinib): The 2037 Generic Opportunity Window

Oct 26, 2026

Krazati (Adagrasib): The 2037-2043 Generic Opportunity Window

Oct 25, 2026

Jaypirca (Pirtobrutinib): The 2036-2041 Generic Opportunity Window

Oct 25, 2026

SUN PHARMACEUTICAL INDUSTRIES INC: DEURUXOLITINIB PHOSPHATE (May 10, 2044): The Generic Opportunity Window

Oct 24, 2026

Camzyos (Mavacamten): The 2034-2036 Generic Opportunity Window

Oct 24, 2026

GOMEKLI (MIRDAMETINIB): The 2041 Generic Opportunity Window

Oct 23, 2026

Welireg (Belzutifan): The 2034-2042 Generic Opportunity Window

Oct 23, 2026

PONVORY (PONESIMOD): The 2032 Generic Opportunity Window

Oct 22, 2026

REZDIFFRA (RESMETIROM): The 2033 Generic Opportunity Window

Oct 21, 2026

Kerendia (Finerenone): The 2033-2037 Generic Opportunity Window

Oct 21, 2026

LAMLIQUE (LAMOTRIGINE HEMIFUMARATE): The 2045 Generic Opportunity Window

Oct 20, 2026

Sotyktu (Deucravacitinib): The 2033-2043 Generic Opportunity Window

Oct 20, 2026

ROMVIMZA (VIMSELTINIB): The 2044 Generic Opportunity Window

Oct 19, 2026

Scemblix (Asciminib): The 2035-2040 Generic Opportunity Window

Oct 19, 2026

LYNKUET (ELINZANETANT): The 2027 Generic Opportunity Window

Oct 18, 2026

AXTLE (PEMETREXED DIPOTASSIUM): The June 25, 2045 Generic Opportunity Window

Oct 17, 2026

Xcopri (Cenobamate): The 2032-2039 Generic Opportunity Window

Oct 17, 2026

Nubeqa (Darolutamide): The 2030-2036 Generic Opportunity Window

Oct 17, 2026

ZUNVEYL (BENZGALANTAMINE GLUCONATE): The 2042 Generic Opportunity Window

Oct 16, 2026

Orgovyx (Relugolix): The 2029-2037 Generic Opportunity Window

Oct 16, 2026

Tukysa (Tucatinib): The 2032-2038 Generic Opportunity Window

Oct 15, 2026

Ubrelvy (Ubrogepant): The 2031-2035 Generic Opportunity Window

Oct 14, 2026

Brukinsa (Zanubrutinib): The 2034-2037 Generic Opportunity Window

Oct 13, 2026

Nuplazid (Pimavanserin): The 2030-2038 Generic Opportunity Window

Oct 13, 2026

Zejula (Niraparib): The 2029-2038 Generic Opportunity Window

Oct 12, 2026

Nurtec ODT (Rimegepant): The 2034-2039 Generic Opportunity Window

Oct 11, 2026

Caplyta (Lumateperone): The 2029-2040 Generic Opportunity Window

Oct 10, 2026

Kisqali (ribociclib): The 2031-2036 Generic Opportunity Window

Oct 10, 2026

Olumiant (baricitinib): The 2029-2032 Generic Opportunity Window

Oct 9, 2026

Ingrezza (valbenazine): The 2031-2038 Generic Opportunity Window

Oct 9, 2026

Ingrezza (valbenazine): The 2036-2038 Generic Opportunity Window

Oct 8, 2026

Cabometyx (cabozantinib): The 2030-2031 Generic Opportunity Window

Oct 8, 2026

Jardiance (Empagliflozin): The 2029 Generic Opportunity Window

Oct 7, 2026

Ofev (Nintedanib): The 2026-2030 Generic Opportunity Window

Oct 5, 2026

Rexulti (Brexpiprazole): The 2027-2032 Generic Opportunity Window

Oct 2, 2026

Austedo (Deutetrabenazine): The 2031-2038 Generic Opportunity Window

Oct 1, 2026

Vyndamax (Tafamidis): The 2028-2035 Generic Opportunity Window

Sep 30, 2026

Erleada (Apalutamide): The 2030-2035 Generic Opportunity Window

Sep 29, 2026

Imbruvica (Ibrutinib): The 2026-2032 Generic Opportunity Window

Sep 28, 2026

Venclexta (Venetoclax): The 2030-2033 Generic Opportunity Window

Sep 27, 2026

Calquence (Acalabrutinib): The 2032-2036 Generic Opportunity Window

Sep 26, 2026

Rinvoq (Upadacitinib): The 2033-2037 Generic Opportunity Window

Sep 25, 2026

Tagrisso (Osimertinib): The 2032 Generic Opportunity Window

Sep 24, 2026

Verzenio (Abemaciclib): The 2031 Generic Opportunity Window

Sep 23, 2026

Lenvima (Lenvatinib): The 2027-2030 Generic Opportunity Window

Sep 22, 2026

Trintellix (vortioxetine): The 2026 Generic Opportunity Window

Sep 21, 2026

Jakafi (Ruxolitinib): The 2028 Generic Opportunity Window

Sep 20, 2026

Xtandi (Enzalutamide): The 2027 Generic Opportunity Window

Sep 19, 2026

Vraylar (Cariprazine): The 2029 Generic Opportunity Window

Sep 18, 2026

Lynparza (Olaparib): The 2027 Generic Opportunity Window

Sep 17, 2026

Otezla (Apremilast): The 2028 Generic Opportunity Window

Sep 15, 2026

Jardiance (Empagliflozin): The 2029 Generic Opportunity Window

Sep 12, 2026

Firdapse (Amifampridine): The 2035 Generic Opportunity Window

Sep 11, 2026

Biktarvy (bictegravir): The 2036 Generic Opportunity Window

Sep 7, 2026

Tivicay (dolutegravir): The 2029 Generic Opportunity Window

Sep 3, 2026

The Enbrel Patent Thicket: A Three-Decade Monopoly (2012-2029)

Sep 3, 2026

Ibrance (palbociclib): The 2027 Generic Opportunity Window

Aug 30, 2026

The Keytruda (Pembrolizumab) Opportunity Window: 2028 to 2042

Aug 30, 2026

The Eliquis (apixaban) Opportunity Window: A Timeline to Generic Entry